Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Inclusion Criteria:

* Japanese subjects ≥ 20 years of age
* ECOG Performance Status of 0 to 1
* Life expectancy of at least 12 weeks
* Subjects with advanced, histologically or cytologically confirmed solid tumors, not amenable to any standard therapy, have no standard therapy available
* Subjects whose fresh or archival tumor tissues are available
* Measurable disease with at least one lesion that can be accurately measured in at least one dimension according to RECIST criteria (Version 1.1 or modified version)
* Adequate bone marrow, liver, and renal function

Exclusion Criteria:

* Anticancer chemotherapy, experimental cancer therapy, or immunotherapy within 2 weeks of start of the first dose
* Impaired cardiac function or clinically significant cardiac disease (i.e., congestive heart failure (CHF) NYHA Class III or IV)
* Myocardial infarction or onset of unstable angina \< 3 months prior to general screening
* Cardiac arrhythmias in the electrocardiogram that would interfere with QT/QTc interval measurement (LBBB (left bundle branch block), AV block, atrial fibrillation)
* QTc \>470 ms, derived as the average of the 3 values measured by the ECG recorder's algorithm on the ECG triplicate
* LVEF (left ventricular ejection fraction) \<50 %
* Uncontrolled hypertension defined as systolic blood pressure \> 150 mm Hg and/or diastolic blood pressure \> 90 mmHg, despite optimal medical management
* Known human immunodeficiency virus (HIV) infection
* Subjects with an active hepatitis B or C infection requiring treatment
* Personal or family history of Long QT Syndrome (LQTS)
* Subject with clinically significant eye disorders